SYNTHESIS OF THIAZOLIDINONE DERIVATIVES BASED ON CITRAL AS POTENTIAL BIOLOGICALLY ACTIVE COMPOUNDS

Authors

DOI:

https://doi.org/10.11603/2312-0967.2026.2.15977

Keywords:

citral, thiazoles, thiazolidones, synthesis, ProTox-IIІ

Abstract

The aim of the work. To synthesize and investigate new thiazole and thiazolidinone derivatives containing a citral fragment, as well as to evaluate their predicted toxicity.

Materials and Methods. The synthesis of the target compounds was carried out using conventional organic synthesis methods. The structures of the obtained products were confirmed by 1H NMR spectroscopy and chromatography–mass spectrometry. For a selected set of synthesized compounds, in silico prediction of oral toxicity was performed using the ProTox-IIІ online platform.

Results. A series of thiazole and thiazolidinone derivatives incorporating a citral fragment into their molecular structure was successfully synthesized with high yields. The analysis of spectral data confirmed the proposed structures of the synthesized compounds. According to the toxicity prediction results, all investigated compounds belong to toxicity class IV (LD₅₀ = 350–1250 mg/kg) and predominantly do not exhibit hepatotoxic, immunotoxic, mutagenic, or cytotoxic effects. For some derivatives, a potential carcinogenic activity was predicted.

Conclusions. The synthesized thiazole and thiazolidinone derivatives containing a citral fragment are characterized by moderate predicted toxicity and may be considered promising molecular platforms for further pharmacological and toxicological studies.

Author Biographies

  • R.M. Khoma , State Non-Profit Enterprise “Danylo Halytsky Lviv National Medical University”

    PhD student of the Department of Pharmaceutical, Organic and Bioorganic Chemistry

  • D. R. Zavodyak, State Non-Profit Enterprise “Danylo Halytsky Lviv National Medical University”

    PhD student of the Department of Pharmaceutical, Organic and Bioorganic Chemistry

  • A. V. Lozynskyi, State Non-Profit Enterprise “Danylo Halytsky Lviv National Medical University”

    ScD (Pharmacy), Professor of the Department of Pharmaceutical, Organic and Bioorganic Chemistry

  • R. B. Lesyk , State Non-Profit Enterprise “Danylo Halytsky Lviv National Medical University

    ScD (Pharmacy), Head of the Department of Pharmaceutical, Organic and Bioorganic Chemistry

References

Sharma S, Habib S, Sahu D, Gupta J. Chemical properties and therapeutic potential of citral, a monoterpene isolated from lemongrass. Med Chem. 2021;17(1):2-12. https://doi.org/10.2174/1573406416666191227111106 DOI: https://doi.org/10.2174/18756638MTAzbMjYa2

Idrees M, Hakkim FL, Naikoo GA, Ul Hassan I. Recent advances in extraction, characterization, and potential use of citral. In: Natural Bio-active Compounds. Vol. 3. Biotechnology, Bioengineering, and Molecular Approaches. 2019. p. 225-236. https://doi.org/10.1007/978-981-13-7438-8_9 DOI: https://doi.org/10.1007/978-981-13-7438-8_9

Southwell I. Backhousia citriodora F. Muell. (Lemon Myrtle), an unrivalled source of citral. Foods. 2021;10(7):1596. https://doi.org/10.3390/foods10071596 DOI: https://doi.org/10.3390/foods10071596

Habib S, Gupta P, Bhat SS, Gupta J. In silico, in-vitro and in vivo screening of biological activities of citral. Int J Vitam Nutr Res. 2021;91(3-4):251-260. https://doi.org/10.1024/0300-9831/a000625 DOI: https://doi.org/10.1024/0300-9831/a000625

Li Y, Mei J, Xie J. Citral: bioactivity, metabolism, delivery systems, and food preservation applications. Compr Rev Food Sci Food Saf. 2025;24(3):e70168. https://doi.org/10.1111/1541-4337.70168 DOI: https://doi.org/10.1111/1541-4337.70168

Hu YR, Ga F, Ch YY, Li SL, Li XL, Ya HK, et al. Research progress of extraction method and biological activity of natural citral. J South Agric. 2023;53(11):3217-3228. https://doi.org/10.3969/j.issn.2095-1191.2022.11.023

Shen Y, Sun Z, Guo X. Citral inhibits lipopolysaccharide-induced acute lung injury by activating PPAR-γ. Eur J Pharmacol. 2015;747:45-51. https://doi.org/10.1016/j.ejphar.2014.09.040 DOI: https://doi.org/10.1016/j.ejphar.2014.09.040

Solon IG, Santos WS, Branco LG. Citral as an anti-inflammatory agent: mechanisms, therapeutic potential, and perspectives. Pharmacol Res Nat Prod. 2025:100253. https://doi.org/10.1016/j.prenap.2025.100253 DOI: https://doi.org/10.1016/j.prenap.2025.100253

Lee HJ, Jeong HS, Kim DJ, Noh YH, Yuk DY, Hong JT. Inhibitory effect of citral on NO production by suppression of iNOS expression and NF-κB activation in RAW264.7 cells. Arch Pharm Res. 2008;31(3):342-349. https://doi.org/10.1007/s12272-001-1162-0 DOI: https://doi.org/10.1007/s12272-001-1162-0

Banerjee P, Eckert AO, Schrey AK, Preissner R. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 2018;46(W1):W257-W263. https://doi.org/10.1093/nar/gky318 DOI: https://doi.org/10.1093/nar/gky318

Banerjee P, Kemmler E, Dunkel M, Preissner R. ProTox 3.0: a webserver for the prediction of toxicity of chemicals. Nucleic acids research. 2024;52(W1):W513-20. https://doi.org/10.1093/nar/gkae303 DOI: https://doi.org/10.1093/nar/gkae303

Published

2026-05-29

Issue

Section

Synthesis of biologically active compounds

How to Cite

SYNTHESIS OF THIAZOLIDINONE DERIVATIVES BASED ON CITRAL AS POTENTIAL BIOLOGICALLY ACTIVE COMPOUNDS. (2026). Pharmaceutical Review Farmacevtičnij časopis, 2, 7-13. https://doi.org/10.11603/2312-0967.2026.2.15977